Repare Therapeutics Inc. — Director's Dealing 2021

Jun 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Repare Therapeutics Inc. (RPTX)
CIK: 0001808158
Period of Report: 2021-06-28

Reporting Person: Foley Todd (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-28	Common Shares	S	6080	$34.06	Disposed	2272367	Indirect
2021-06-28	Common Shares	S	1190	$34.82	Disposed	2271177	Indirect
2021-06-29	Common Shares	S	1190	$33.29	Disposed	2269987	Indirect

Footnotes

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

F2: The shares were sold as follows: 5,878 by MPM BioVentures 2014, L.P. ("BV 2014") and 202 by MPM Asset Management Investors BV2014 LLC ("AM BV2014").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.59 to $34.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,065,432 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 71,092 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: The shares were sold as follows: 1,150 by BV 2014 and 40 by AM BV2014.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.60 to $35.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,064,282 by BV 2014, 135,843 by BV 2014(B) and 71,052 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The shares are held as follows: 2,063,132 by BV 2014, 135,843 by BV 2014(B) and 71,012 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.